The following has just turned up in my inbox from Tristel. LON:TSTL (I hold)

United States Environmental Protection Agency (EPA)

Tristel received its first approval from the EPA for its foam-based disinfectant for surfaces in April 2018. We successfully enhanced the performance claims of the product with a second approval in January 2019 and then registered the product in three States before curtailing the nationwide registration programme until a third submission could be made to bolster further the competitive positioning of the product. This submission was made in October 2020 and we have now received the third approval for Jet. This expands the product’s efficacy claims to include mycobacteria, and all efficacy claims are within a contact time of two minutes. We expect to complete State-by-State registration by the end of June 2022, including California where our existing registration will require amendment, which can be a lengthy process.

We have appointed Parker Laboratories, New Jersey, as our United States manufacturing partner for Jet and will sell the product through Parker’s nationwide network of distributors on a non-exclusive basis, commencing in FY23. Other distribution channels will be put in place ahead of the US launch.


It has not come through RNS and has not been release pre-market - but the news seem pretty important to me.  I read that this as regulatory approval is finally happening, even if getting FDA approval is nearly as difficult as selling shellfish to the French!   (see the BBC news site). Any views from other investors? 

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here